Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
Top Cited Papers
- 17 May 2010
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 29 (28), 4018-4032
- https://doi.org/10.1038/onc.2010.154
Abstract
A hallmark of cancer is the deregulation of cell-cycle machinery, ultimately facilitating aberrant proliferation that fuels tumorigenesis and disease progression. Particularly, in breast cancers, cyclin D1 has a crucial role in the development of disease. Recently, a highly specific inhibitor of CDK4/6 activity (PD-0332991) has been developed that may have efficacy in the treatment of breast cancer. To interrogate the utility of PD-0332991 in treating breast cancers, therapeutic response was evaluated on a panel of breast cancer cell lines. These analyses showed that the chronic loss of Rb is specifically associated with evolution to a CDK4/6-independent state and, ultimately, resistance to PD-0332991. However, to interrogate the functional consequence of Rb directly, knockdown experiments were performed in models that represent immortalized mammary epithelia and multiple subtypes of breast cancer. These studies showed a highly specific role for Rb in mediating the response to CDK4/6 inhibition that was dependent on transcriptional repression manifest through E2F, and the ability to attenuate CDK2 activity. Acquired resistance to PD-03322991 was specifically associated with attenuation of CDK2 inhibitors, indicating that redundancy in CDK functions represents a determinant of therapeutic failure. Despite these caveats, in specific models, PD-0332991 was a particularly effective therapy, which induced Rb-dependent cytostasis. Combined, these findings indicate the critical importance of fully understanding cell-cycle regulatory pathways in directing the utilization of CDK inhibitors in the clinic.Keywords
This publication has 48 references indexed in Scilit:
- 3,3′-Diindolylmethane induces a G1 arrest in human prostate cancer cells irrespective of androgen receptor and p53 statusBiochemical Pharmacology, 2009
- Retinoblastoma/p107/p130 Pocket ProteinsJournal of Biological Chemistry, 2009
- Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancerAnnals of Oncology, 2009
- A Novel Gene Signature for Molecular Diagnosis of Human Prostate Cancer by RT-qPCRPLOS ONE, 2008
- Tailoring to RB: tumour suppressor status and therapeutic responseNature Reviews Cancer, 2008
- p21 and p27: roles in carcinogenesis and drug resistanceExpert Reviews in Molecular Medicine, 2008
- Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer CellsPublished by Elsevier BV ,2001
- Molecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene, 2000
- The Hallmarks of CancerCell, 2000
- Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survivalEuropean Journal of Cancer, 1995